BC Innovations | Nov 1, 2019
Product Development

Adrenomed looks beyond immune modulators for sepsis, aims for shock prevention

By targeting a new mechanism further downstream in the sepsis pathway than previous approaches, Adrenomed thinks it can escape the graveyard that has sunk drug development in the indication. Its approach hinges on preventing the...
BC Week In Review | Nov 30, 2018
Financial News

Adrenomed raises €24M series D

Adrenomed AG (Hennigsdorf, Germany) raised €24 million ($27.3 million) in a series D round led by new investors Wellington Partners and HBM Healthcare Investments, with participation from existing investors ILB, ExpoCapital GmbH and company founders....
Items per page:
1 - 2 of 2